crenigacestat: Clinical Trials

8 trials of crenigacestat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 terminated. 8 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 6, Terminated 2
Phase 21Completed 1

Follow crenigacestat: new trials by email Literature Review of crenigacestat trials Research Report on crenigacestat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
BCMA-specific CAR-expressing T Lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Phase 1TerminatedFred Hutchinson Cancer Center192018-05-232024-01-08
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
LY3039478, Taladegib, Abemaciclib - Solid Tumor, Breast Cancer
Phase 1TerminatedEli Lilly and Company942016-11-042025-08-21
Study of LY3039478 in Healthy Participants
LY3039478, 13C 15N 2H-LY3039478 IV - Healthy
Phase 1CompletedEli Lilly and Company122016-10-042025-07-09
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
LY3039478 - Advanced Solid Tumor
Phase 1CompletedEli Lilly and Company112016-09-092025-08-07
A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants
LY3039478 - Healthy
Phase 1CompletedEli Lilly and Company62016-09-012025-07-28
A Study of LY3039478 in Healthy Participants
Placebo, LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1) - Healthy
Phase 1CompletedEli Lilly and Company292016-01-012025-08-12
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
LY3039478, Dexamethasone, Placebo - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Phase 1 / Phase 2CompletedEli Lilly and Company362015-10-012019-09-11
A Study of LY3039478 in Participants With Advanced Cancer
LY3039478, Prednisone - Neoplasms, Neoplasm Metastasis
Phase 1CompletedEli Lilly and Company2472012-10-012025-12-26

Conditions studied

Breast Neoplasms (1)  ·  Cholangiocarcinoma (1)  ·  Colonic Neoplasms (1)  ·  Lymphoma (1)  ·  Multiple Myeloma (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Sarcoma (1)

Sponsors

Eli Lilly and Company (7)  ·  Fred Hutchinson Cancer Center (1)

Countries

United States (6)  ·  France (3)  ·  Denmark (2)  ·  Germany (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)

Top investigators

Andrew Cowan (1)

Results publications

PMID 30060061, PMID 30218977, PMID 31558469, PMID 32915419, PMID 32939607, PMID 33107983, PMID 33686452, PMID 36030462, PMID 37414012, PMID 40756609

NIH funding

2014 (1), 2015 (1), 2016 (1)